The goal of this work was to examine the effect of different solvents (Water, EtOH 70%, and acetone) on the phenolic composition, antioxidant, and antibacterial capacity of Moroccan Mentha aquatica L. leaf extract. To this end, HPLC-ESI-FULL-MS was used to characterize the extracts, while the Folin-Ciocalteu and aluminum trichloride techniques were used to evaluate the total phenolic and flavonoid contents. To assess the antibacterial capacity, the microdilution technique was performed to calculate the minimal inhibition concentration (MIC), and minimal bactericidal concentration (MBC). Phytochemical profiling revealed that the extracts were rich in bioactive constituents, particularly ferulic acid derivative, caffeoyl-protocatechuic acid derivative, quercetin, and diosmetin 7-O-beta-D-glucuronide. The hydroethanolic extract contained the highest levels of total phenolic (62.2 ± 1.2 mg GAE/g DW) and flavonoid (29.15 ± 0.09 mg QE/g DW) contents, exceeding those of the acetonic extract (22.2 ± 0.6 and 10.17 ± 0.07 mg GAE/g DW, respectively) and the water extract (22.4 ± 0.6 and 10.9 ± 0.6 mg QE/g DW, respectively). This extract also showed the strongest antioxidant effect, recording an IC50 of 0.060 ± 0.001 mg/mL in the DPPH assay, and an EC50 of 80 µg/mL in the RP test. In addition, it shows a great total antioxidant capacity, reaching 75.1 ± 2.0 mg EAA/g DW when compared to water and acetonic extracts (28.5 ± 1.4 and 21.1 ± 0.1 mg EAA/g DW, respectively). The antibacterial potential ranges from 0.78 ± 0.05 mg/mL to 12.6 mg/mL. In-silico prediction highlighted diosmetin 7-O-beta-D-glucuronide, quercetin, and equisetumpyrone as the key contributors to antioxidant capacity, while quercetin, 2,3,8-Tri-O-methylellagic acid, and diosmetin 7-O-beta-D-glucuronide were involved in antibacterial activity.
Journal of Computational Biophysics and Chemistry · 1-20
The pursuit of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors continues to be a key approach in anticancer drug discovery. In this context, a new benzanilide-based derivative, Z-CMPBC, was designed following essential VEGFR-2 pharmacophoric requirements and investigated through combined computational and biological approaches. Density functional theory (DFT) calculations at the B3LYP/6-31[Formula: see text]G(d, p) level indicated favorable electronic characteristics, including balanced chemical hardness and pronounced electrophilicity, suggesting a strong propensity for interaction within kinase active sites. Molecular docking, supported by 200 ns molecular dynamics simulations, demonstrated stable accommodation of the compound within the VEGFR-2 binding pocket. Binding free energy calculations using the MM-GBSA method revealed a significant interaction profile ([Formula: see text] kcal/mol), mainly governed by van der Waals forces and persistent hydrophobic interactions with critical residues. Biological assessment confirmed potent VEGFR-2 inhibition, with an IC[Formula: see text] value of [Formula: see text]M, closely comparable to sorafenib ([Formula: see text]M). Western blot analysis further verified a reduction in phosphorylated VEGFR-2 (pY1054/Y1059) levels in MCF-7 cells, supporting effective intracellular kinase inhibition. Additionally, Z-CMPBC exhibited pronounced cytotoxicity, particularly against MCF-7 breast cancer cells (IC[Formula: see text]M), along with a high selectivity index ([Formula: see text]) relative to normal Vero cells. Flow cytometry analysis demonstrated induction of G0/G1 phase arrest, accompanied by enhanced apoptotic activity (34.05%) compared to untreated cells. In silico ADMET and toxicity predictions suggested acceptable pharmacokinetic behavior and safety characteristics. Overall, these findings highlight Z-CMPBC as a promising VEGFR-2 inhibitor with potential for further development as an anticancer agent.
VEGFR-2 inhibitorsanticancer drug discoverykinase inhibitorsMCF-7 cells
We present a modular microfluidic platform for constructing miniaturized, compartmentalized cell culture systems that support monoculture, co-culture, and organ-on-a-chip models of human tissues. The devices provide architecturally defined three-dimensional microenvironments in which heterogeneous cell populations can be cultured in close proximity while maintaining precise spatial organization and independent access to each compartment. In vivo-like perfusion into, from, and between adjacent chambers is achieved via micro-engineered porous barriers that act as perfusion microchannels, enabling controlled convective and diffusive transport and recapitulating paracrine signaling between tissue units. As a proof of concept, we implement an adipose-immune co-culture model that reproduces key features of inflamed, insulin-resistant adipose tissue, including altered cytokine secretion and glucose uptake. Together, these features establish a versatile platform for the biofabrication of customizable single-organ and multi-organ in vitro models that more faithfully recapitulate human tissue structure and function for applications in disease modeling, immunometabolic studies, and preclinical drug testing.
Broccoli (Brassica oleraceae L. var. italica) is an important crop and faces challenges of further propagation due to genetic segregation and climate change. Efficient micropropagation protocols are necessary for the rapid production of true-to-type plantlets and are essential for this process. However, the synergistic effects of 6-benzylaminopurine (BAP) and gibberellic acid (GA₃) for this species have not been extensively studied. The study evaluated five pre-sowing seed-soaking treatments with various concentrations of BAP and GA₃ (Control: T₀; T₁: 25 + 25; T₂: 25 + 50; T₃: 50 + 25; T₄: 50 + 50 ppm) on Murashige and Skoog (MS) medium over a 16 h photoperiod, using a completely randomized design (CRD) with individual in vitro seedlings as experimental units. Morphological, physiological, biochemical, antioxidant, and gene expression (RT-qPCR) parameters were assessed.. All hormonal treatments significantly exhibited better response as compared to the control (T₀) treatment (p ≤ 0.05). The application of hormonal treatment (25 ppm BAP + 50 ppm GA3) (T2) significantly better response with an increase in shoot length and elevation in plant biomass, chlorophyll (a, b and T Chl), total phenolic content (TPC), flavonoids (TFC) and DPPH scavenging activity. Antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT) and peroxidase (POD) and seedling vigor index (SVI-I, SVI-II) were significantly increased under T₂, markedly a mitigating enzyme activity. RT-qPCR analysis further confirmed these results by showing high levels of transcript abundance of antioxidant-related genes (BoSOD1, BoAPX1 and BoCAT) under T2 than in the control group with amplification specificity verified through melt curve analysis. Multivariate analyses, correlation heatmap, network analysis and principal component analysis indicated significant positive interrelationships among the growth traits, photosynthetic pigments, antioxidant capacity and vigor indices, implying the coordinated physiological regulation. Similarly, T2 as an efficient hormonal approach to enhance growth, antioxidant control, in vitro micropropagation efficiency in broccoli.
Human physiology is a complex process encompassing various biochemical mechanisms, regulated by hundreds of chemical mediators, thus making it more complicated to understand. Balance between these mediators is mandatory to continue the helm of life; however, an imbalance can disrupt normal physiological functions and lead to chronic health conditions. Cancer is one such chronic state that occurs due to an imbalance or overproduction of reactive oxygen and nitrogen species (RONS), which are highly unstable and damage other chemical constituents in the body. The mutilation at the cellular level results in DNA and genetic mutation, uncontrolled cell proliferation, metastasis, organ dysfunction, and ultimately mortality. Various types of cancers are intimidating human life globally, and lung cancer is leading them all, followed by breast and colorectal cancer. Oxidative stress (OS) is the main root cause of cancers that occur due to overproduced RONS. Tumor suppressor genes (TSGs) like p53, PTEN, INK4, MADR2, APC, and oncogenes such as HER2, BCR/ABL1, CMYC, EML4AK, RAS, WNT, ERK, and TRK get mutated by OS. Moreover, various pro-inflammatory markers i.e., IL-1, IL-6, TNF-α, IFN-γ, TGF-β and growth factors (VEGF, EGF, IGF-2) are also involved in cancer progression. Along with these aspects, the oncogenesis involves different signaling pathways/axis such as MAPK, PI3K, mTOR, Wnt/β-catenin, GSK3, and NF-κB. Epigallocatechin gallate (EGCG), a bioactive compound abundantly existing in green tea and grapes with strong antioxidant activity and anticancer potential, is a suitable approach to reduce the cancer burden. The in vitro and in vivo anticancer studies of EGCG proved anticancer and anti-tumor effects through modulation of cancer signaling pathways, reduction in cell proliferation, decreased metastasis, suppressed angiogenesis, enhanced antioxidant activity, inhibited pro-inflammatory biomarkers, improved TSGs expression, and downregulated oncogenes expression. Shortly, the current review focuses on the anticancer potential of EGCG through possible mechanisms.
Introduction: Inhibiting cyclooxygenase-2 (COX-2) is a potential strategy in inflammation therapy. Thus, developing COX-2 inhibitors plays a pivotal role in efficient inflammation treatment. This study discloses the synthesis of new heterocyclic compounds incorporating pyridine, pyran, and/or pyrazole moieties as COX-2 inhibitors. Methods: In this study, the Claisen–Schmidt reaction of 1-(5-hydroxy-1,3-diphenyl-1H-pyrazol-4-yl)ethan-1-one 1 and p-methoxybenzaldehyde in ethanol containing aqueous sodium hydroxide (10%) led to the formation of 1-(5-hydroxy-1,3-diphenyl-1H-pyrazol-4-yl)-3-(4-methoxyphenyl)prop-2-en-1-one) 2. The latter compound was allowed to react as a key precursor with various nucleophiles such as ethyl cyanoacetate, malononitrile, cyclohexanone, ethyl acetoacetate, hydrazine, cyano acid hydrazide, hydrazide, and/or thiosemicarbazide to yield new heterocyclic derivatives comprising pyridine, pyran, and/or pyrazole moieties 3–15, according to the Michael addition reaction. The newly synthesized compounds were depicted using spectroscopic techniques such as IR, 1H-NMR, 13C-NMR, and MS. Moreover, their anti-inflammatory efficiency was in vitro evaluated by means of protein denaturation inhibition and cell membrane protection assay. Results: The results of 2−ΔΔct values of COX-2 expression for compounds 6, 11, 12, and 13 were 6.6, 2.9, 25.8, and 10.1, respectively. Therefore, compound 12, followed by 13, 11, and 6, showed potent anti-inflammatory properties by in vitro evaluation. Further, an in silico molecular docking study was performed on the best-docked compounds and reference drug (Diclofenac) to investigate their binding affinities against the active site of the target enzyme. The obtained results from the in silico study aligned with the biological evaluation. Conclusions: The studies open new doors for designing new heterocycles containing pyridine, pyran, and/or pyrazole moieties as potent anti-inflammatory agents.
Current Medicinal Chemistry · مجلد 32 (29) · 6353-6379
INTRODUCTION: In our quest to identify potent inhibitors against SARS-CoV-2, an extensive investigation was conducted for the binding and inhibitory efficacy of Rutin against nine SARS-CoV-2 proteins. METHODS: Structure Similarity, flexible alignment, Molecular Docking, molecular dynamics (MD) simulations and in vitro assays against the RdRp and SARS-CoV-2 have been conducted. RESULTS: The first step of our analysis involved a comprehensive examination of structural similarity among the co-crystallized ligands associated with those proteins. A substantial structural similarity was observed between Rutin and Remdesivir, the ligand of the SARS-CoV-2 RNAdependent RNA polymerase (RdRp). This similarity was validated through a flexible alignment study. Molecular docking studies, involving superimposition, revealed a notable resemblance in the mode of binding between Rutin and Remdesivir inside the active site of the RdRp. A 200 ns MD simulation confirmed that the RdRp-Rutin complex is more stable than the RdRp-Remdesivir complex. The MM-GBSA studies showed that Rutin had much more favorable binding energies, with a significantly lower value of -7.76 kcal/mol compared to Remdesivir's -2.15 kcal/mol. This indicates that the RdRp-Rutin binding is more robust and stable. PLIP and ProLIF studies helped clarify the 3D binding interactions and confirmed the stable binding seen in MD simulations. PCAT gave more insights into the dynamic behavior of the RdRp-Rutin complex. In vitro tests showed that Rutin has a strong inhibitory effect on RdRp with an IC50 of 60.09 nM, significantly outperforming Remdesivir, which has an IC50 of 24.56 μM. Remarkably, against SARS-CoV-2, Rutin showed a superior in vitro IC50 of 0.598 μg/ml compared to Remdesivir (12.47 μg/ml). The values of the selectivity index underscored the exceptional margin of safety of Rutin (SI: 1078) compared to Remdesivir (SI: 5.8). CONCLUSION: In conclusion, our comprehensive analysis indicates Rutin's promising potential as a potent SARS-CoV-2 RdRp inhibitor, providing a valuable insight for developing an effective COVID-19 treatment.
ADMET analysis predicted a favorable safety profile over sorafenib, particularly with respect to carcinogenic and chronic toxicity risks. These findings indicate that quinoxaline derivative 11d holds potential as a selective and effective VEGFR-2 inhibitor with promising antitumor and anti-metastatic properties, warranting further investigation.
Journal of Infection and Public Health · مجلد 18 (6) · 102763-102763
Leprosy and tuberculosis caused by Mycobacterium leprae and Mycobacterium tuberculosis, respectively, are chronic infections with significant public health implications. While leprosy affects the skin and peripheral nerves and tuberculosis primarily targets the lungs, both diseases involve systemic immune responses. This study integrates transcriptomic analysis cheminformatics and molecular dynamics simulations to identify molecular mechanisms and potential therapeutic targets. Transcriptomic datasets were analyzed to identify dysregulated genes and pathways. Pathway enrichment tissue-specific and bulk RNA-seq expression analyses provided biological context. System biology networks revealed regulatory hub genes and molecular docking studies evaluated CHEMBL compounds as potential therapeutics. Molecular dynamics (MD) simulations assessed the stability of top ligand-protein complexes through RMSD RMSF and MM-GBSA free energy calculations. Gene expression analysis identified 13 core dysregulated genes, including HSP90AA1 MAPK8IP3 and ZMPSTE24. Tissue-specific expression localized pivotal genes to lung tissues and immune cells with HSP90AA1 highly expressed in alveolar macrophages and epithelial cells. HSP90AA1 gene emerged as a central hub gene with 96 interactions involved in stress response pathways. Docking studies identified CHEMBL3653862 and CHEMBL3653884 with strong binding affinities (-10.16 to −12.69 kcal/mol) interacting with Asp93 and Tyr139. MD simulations confirmed binding stability with RMSD fluctuations within 2.1–3.5 Å and MM-GBSA energy values supporting ligand-protein stability. This study identifies HSP90AA1 as a potential drug target in leprosy and tuberculosis. Findings support host-directed therapy approaches and highlight the importance of computational modeling in accelerating drug discovery. The study provides a foundation for future experimental validation, including in vitro and in vivo testing to advance drug repurposing strategies for these chronic infections. • Identified 13 shared dysregulated genes between tuberculosis and leprosy. • Uncovered critical pathways and protein-protein interactions using network medicine. • Highlighted roles of genes in immune-related cells through tissue-specific and single-cell gene expression analyses. • Conducted drug repurposing analysis, identifying CHEMBL compounds with strong binding affinities for key targets. • Deliver a comprehensive understanding of disease mechanisms and therapeutic opportunities.
BACKGROUND: Topoisomerase II (Topo II) remains a validated target for anticancer therapy, with many clinically used agents acting via DNA intercalation and enzyme inhibition. However, their clinical use is limited by severe toxicity and resistance. In this study, we investigate aotaphenazine, a rare hydrophenazine derivative isolated from Streptomyces sp. IFM 11694 as a potential novel Topo II inhibitor with selective anticancer activity. METHODS: Molecular docking and 400 ns molecular dynamics (MD) simulations were employed to evaluate aotaphenazine's binding mode within the DNA-Topo II complex (PDB: 3QX3). MM-GBSA calculations quantified interaction energetics, while ProLIF and PLIP analyses detailed the interaction patterns. Topo II inhibition was assessed via in vitro enzymatic assays. Cytotoxicity (MTT) assays were conducted against a panel of human cancer and normal cell lines. Flow cytometry was used to evaluate apoptosis and cell cycle progression in MDA-MB-231 cells. RESULTS: aotaphenazine demonstrated a docking binding energy of -19.12 kcal/mol and remained stably intercalated within the DNA groove during MD simulations. MM-GBSA analysis showed a total binding free energy of -29.81 kcal/mol, driven primarily by van der Waals forces. Interaction profiling identified consistent π-stacking with Cyt8 and Thy9, and strong binding contributions from Ade12 and Gua13. Enzymatic assays confirmed Topo II inhibition with an IC50 of 45.01 nM, comparable to doxorubicin (30.16 nM). In vitro cytotoxicity analysis revealed moderate activity across cancer cell lines (IC50 = 26.30-54.35 µM) and significantly reduced toxicity in normal WI-38 and WISH cells (IC50 = 69.86 µM and 84.72 µM, respectively). Flow cytometry showed that aotaphenazine induced early (20.98%) and late apoptosis (42.80%), along with S-phase cell cycle arrest (43.99%) and a marked reduction in the G2/M population in MDA-MB-231 cells. CONCLUSION: aotaphenazine exhibits a compelling combination of Topo II inhibition, DNA intercalation, and selective anticancer activity, supported by both computational modeling and biological validation. Its lower cytotoxicity toward normal cells and ability to induce apoptosis and cell cycle arrest suggest strong therapeutic potential. These findings establish aotaphenazine as a promising lead compound for the development of safer and more selective Topo II-targeting anticancer agents.
topoisomerase II inhibitionDNA intercalationanticancer activitynatural product isolation
BACKGROUND: Primary osteoblasts are essential for bone formation and regeneration, making them pivotal in dental applications, including periodontal regeneration, ridge augmentation, and implant osseointegration. Sourced from various tissues like alveolar bone, calvarial bone, mandibular and maxillary bones, long bones, and bone marrow-derived stem cells (BMSCs), each type of osteoblast presents unique advantages and limitations related to yield, accessibility, and clinical relevance. Given these variables, selecting an appropriate source is crucial for experimental consistency and translational application in dentistry. METHODS: This review synthesizes data from in vitro, animal, and clinical studies to provide a comprehensive overview of osteoblast sourcing, isolation, and characterization in dental research. Sources were reviewed based on yield, anatomical relevance, and accessibility, while isolation methods were compared to assess their impact on cell behavior and phenotype retention. The review evaluates methods such as enzymatic digestion, explant culture, and differentiation of BMSCs, alongside characterization techniques like morphological analysis, gene expression profiling, and mineralization assays. RESULTS: The analysis shows that alveolar bone-derived osteoblasts offer high clinical relevance due to their anatomical similarity to oral structures but are limited by low yield and invasive collection. Calvarial and long bone osteoblasts provide higher yields, making them useful for material testing, though they lack biomechanical compatibility with oral environments. BMSCs offer a renewable source with significant regenerative potential but require precise differentiation protocols. In vitro studies contribute mechanistic insights, while animal models bridge the gap to clinical application, despite challenges in standardization and interspecies variability. CONCLUSION: This review highlights the importance of selecting appropriate osteoblast sources and methods for dental research to optimize outcomes in periodontal and implant-related therapies. The variability across study designs and experimental outcomes underscores the need for standardized protocols and targeted systematic reviews within specific research settings. These findings offer a framework for future osteoblast-based research and guide the effective translation of osteoblast therapies into clinical dental practice.
osteoblast isolationdental tissue regenerationbone marrow-derived stem cellsalveolar bone
This study demonstrates the green synthesis, characterization, and biomedical applications of zinc oxide nanoparticles (ZnONPs) using Zingiber officinale (Z. officinale) (ginger) peel extract. Green synthesis offers advantages over conventional methods, including environmental friendliness, cost-effectiveness, and enhanced biocompatibility. Ultraviolet-Visible (UV-Vis) spectroscopy confirmed ZnONPs formation with a peak at 364 nm. Fourier-Transform Infrared (FTIR) spectroscopy analysis revealed characteristic peaks indicating functional groups involved in nanoparticle formation. Scanning Electron Microscope (SEM) analysis showed spherical/agglomerated nanoparticles, and Energy-Dispersive X-ray Spectroscopy (EDS) confirmed 77.7% zinc oxide by mass%. The X-ray Diffraction (XRD) indicated an average particle size of 24.67 nm with distinct crystal orientations. Phytochemical analysis detected alkaloids, saponins, and steroids in the extract. Optimal synthesis occurred at 50-60°C and pH 10, yielding stable ZnONPs. The ZnONPs exhibited significant antibacterial activity against Staphylococcus aureus (S. aureus), Bacillus subtilis (B. subtilis), Bacillus cereus (B. cereus), Escherichia coli (E.coli), Zymomonas mobilis (Z. mobilis), and Pseudomonas aeruginosa (P. aeruginosa), as well as antifungal activity against Candida albicans (C. albicans). The in vitro cytotoxicity study on M.D. Anderson - Metastatic Breast - 231 (MDA-MB-231) breast cancer cells showed a dose-dependent reduction in cell viability [Half-maximal Inhibitory Concentration (IC50) = 82.13 µg/mL] with notable morphological changes at higher concentrations. The ZnONPs synthesized from ginger peel extract are innovative, environmentally friendly, and economical. Our findings show that biologically generated ZnONPs are effective antibacterial and antifungal agents against several pathogens. This research uniquely demonstrates the potential of ginger peel, a commonly discarded agro-waste, as a sustainable source for ZnONPs synthesis, highlighting its biotechnological and medicinal applications. The novelty of this study lies in the green synthesis approach using ginger peel and the comprehensive evaluation of its antimicrobial and anticancer properties. Further in-depth studies and optimization are needed to validate their therapeutic efficacy and safety.
INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) is a well-established therapeutic target in cancer treatment. In this study, a novel N-phenylacetamide derivative of theobromine, designated as T-1-PA, was designed as a potential semisynthetic EGFR inhibitor. METHOD: The 3D structure, stability, and electronic reactivity of T-1-PA were determined using Density Functional Theory (DFT) analyses. Molecular docking, molecular dynamics (MD) simulations, Molecular Mechanics Generalized Born Surface Area (MM-GBSA), Protein-Ligand Interaction Profiler (PLIP), and Principal Component Analysis of Trajectories (PCAT) were employed to evaluate the binding affinity and inhibitory potential of T-1-PA against EGFR. Computational ADMET profiling was conducted to predict drug-likeness and safety. Subsequently, T-1-PA was semisynthesized and subjected to in vitro biological evaluation. RESULTS: Computational analyses demonstrated a strong binding affinity of T-1-PA to EGFR. The compound exhibited favorable ADMET properties. In vitro assays revealed potent EGFR inhibition with an IC₅₀ of 0.736 ± 0.005 μM. T-1-PA also inhibited the proliferation of HepG2 and MCF7 cancer cell lines with IC₅₀ values of 0.88 ± 0.01 μM and 1.13 ± 0.01 μM, respectively. Flow cytometry analysis indicated induction of apoptosis and G1 phase cell cycle arrest in HepG2 cells. Additionally, T-1-PA significantly impaired HepG2 cell migration and wound-healing capacity. DISCUSSION: The results validate the computational predictions and highlight the anticancer potential of T-1-PA through EGFR inhibition and antiproliferative activity. The compound's favorable pharmacokinetic and safety profiles further support its therapeutic promise. CONCLUSION: T-1-PA is a promising semisynthetic compound with selective antiproliferative activity mediated via EGFR inhibition. These findings encourage further preclinical investigation of T-1-PA as a novel candidate for EGFR-targeted cancer therapy.
BACKGROUND: Vascular endothelial growth factor receptor-2 (VEGFR-2) is a validated target in cancer therapy. However, approved inhibitors like sorafenib are often limited by off-target toxicity and resistance. This study aimed to develop novel thiadiazole-based VEGFR-2 inhibitors with improved selectivity and safer profiles. METHODS: A series of 2,3-dihydro-1,3,4-thiadiazole derivatives was rationally designed, synthesized, and structurally characterized. In vitro cytotoxicity was assessed against MCF-7, HepG-2, HCT-116, and normal WI-38 cells. Mechanistic assays included flow cytometry for cell cycle and apoptosis, and ELISA for caspase-3, Bcl-2, and Bax expression. Molecular docking, 200-ns molecular dynamics (MD) simulations, density functional theory (DFT) calculations, and in silico toxicity profiling supported experimental findings. RESULTS: Compound 11a exhibited the most potent and selective activity (IC₅₀: 9.49 µM for MCF-7, 12.89 µM for HepG-2; SI > 3). It induced >70% apoptosis and dual-phase (S and G2/M) cell cycle arrest. VEGFR-2 inhibition (IC₅₀ = 0.055 µM) was comparable to sorafenib. Computational studies confirmed stable binding at VEGFR-2 active sites. CONCLUSION: Compound 11a is a promising thiadiazole-based candidate with notable in vitro potency, selectivity, and mechanistic activity, supporting its potential for further pharmacokinetics/toxicity evaluation and structural refinement as a VEGFR-2-targeted agent.
VEGFR-2 inhibitorsthiadiazole derivativesanticancer drug discoveryapoptosis induction